What is CagriSema?

The problem with only hitting one system

Semaglutide works. So does tirzepatide. But they both operate through the same basic architecture: activate GLP-1 receptors in the hypothalamus, slow gastric emptying, and cut appetite signals from the gut to the brain. Tirzepatide adds GIP, which amplifies the effect and reduces nausea. The mechanism is better. But the pathway is the same general neighborhood.

Amylin is different. It is a hormone secreted by the beta cells of the pancreas at the same time as insulin — every time you eat. Its job is to signal satiety through the brainstem: specifically the area postrema and the nucleus tractus solitarius. That is not where GLP-1 drugs do most of their work. Two separate systems, converging on fullness from different directions.

In people with obesity and type 2 diabetes, amylin secretion is often impaired. The signal that should be saying “you have eaten enough” is quieter than it should be. Replacing it — or augmenting it — is a reasonable idea.

What cagrilintide is

Cagrilintide is a synthetic amylin analog. More precisely, it is a dual agonist at the amylin receptor and the calcitonin receptor. It mimics amylin but with a much longer half-life, which is why once-weekly dosing works. Amylin itself degrades in hours. Cagrilintide stays in circulation long enough to maintain the signal across a week.

Alone, in a Phase 3 trial arm, cagrilintide produced 11.8% weight loss at 68 weeks. That is meaningful on its own. But it is clearly weaker than semaglutide at 16.1%. The hypothesis behind CagriSema is that combining the two systems produces more than either alone — and the REDEFINE 1 data suggests that hypothesis was correct.

What the CagriSema REDEFINE 1 trial found

REDEFINE 1 was a large, four-arm trial: CagriSema, semaglutide alone, cagrilintide alone, and placebo. 3,417 adults with obesity or overweight but without type 2 diabetes. 68 weeks. Published in the New England Journal of Medicine in December 2025.

The 6.6 percentage point improvement over semaglutide alone is real and statistically significant. At 200 lbs, that gap means an additional 13 lbs lost. At 250 lbs, it is 16 lbs. Not transformative, but not trivial either — and it came from a mechanism that has never been deployed in a commercial obesity drug before.

REDEFINE 2 enrolled adults with type 2 diabetes alongside obesity. CagriSema produced roughly 16% weight loss there, combined with a 1.91% reduction in HbA1c — both superior to semaglutide alone in the same trial. The diabetes angle is significant because blood sugar control is a separate outcome from weight, and CagriSema moved both.

CagriSema vs. tirzepatide: where it lost

REDEFINE 4 was the head-to-head. 809 adults with obesity plus at least one comorbidity. CagriSema 2.4mg/2.4mg versus tirzepatide 15mg, the highest approved dose. The result: CagriSema 23%, tirzepatide 25.5%. The full breakdown of what REDEFINE 4 found and what it means for the next generation is covered separately.

That 2.5 percentage point gap was not just a number. CagriSema failed to demonstrate non-inferiority to tirzepatide — meaning it could not prove it was at least as good. For a drug that needed to position itself as the next step up from Wegovy, losing to the current leader is a real problem.

The comparison is not entirely clean. Tirzepatide 15mg is a high dose. It is also a dual agonist that has been on the market long enough to accumulate substantial real-world tolerability data. CagriSema is newer, and its side effect profile — predominantly GI events similar to other GLP-1 drugs — is still being characterized in longer follow-up. But the head-to-head data is what it is.

Why the amylin mechanism still matters

Losing to tirzepatide in one trial does not make amylin agonism a dead end. There are real reasons to think CagriSema occupies a useful place even if it never outperforms tirzepatide on raw weight loss numbers.

First, CagriSema starts from semaglutide, not tirzepatide. The drug class is not a competition between two molecules looking for the same slot — it is a different pairing for patients who are already on semaglutide, or who respond better to semaglutide than tirzepatide for GI tolerability reasons. Adding cagrilintide to their existing drug is a different question than switching to tirzepatide.

Second, the brainstem satiety pathway is genuinely distinct from GLP-1 hypothalamic signaling. Researchers believe hitting two independent systems may produce more durable weight loss — less plateau, less rebound on maintenance. That hypothesis has not been tested at scale yet. CagriSema is the first drug capable of testing it in a real-world population.

Third, retatrutide adds a glucagon receptor to the mix, and amycretin takes a unimolecular approach to the same GLP-1/amylin combination, posting 24.3% in Phase 2. The competitive landscape by late 2027 or 2028 will look different from today. CagriSema does not need to be the best drug forever. It needs to be useful for the patients it fits. See how the two next-generation front-runners compare directly in retatrutide vs CagriSema. Lilly is taking a third approach with eloralintide, an amylin-only drug tested standalone and alongside tirzepatide rather than fused to a GLP-1 in one molecule.

Where CagriSema stands now

Novo Nordisk is betting that the amylin mechanism justifies a separate market position even without beating tirzepatide outright. The FDA does not require a drug to beat existing competitors — it requires it to be safe and effective versus placebo. On that bar, CagriSema passes clearly.

The commercial question — how payers and prescribers position it against tirzepatide, oral GLP-1 options, and eventually retatrutide — will be answered by the market, not the clinical trials. For now, if you need treatment today, tirzepatide is what is available and FDA-approved.

What to watch for

Two things will determine CagriSema's real-world trajectory after approval. One is insurance coverage — whether payers treat it as interchangeable with Wegovy or as a distinct option. If it lands on formularies at a higher tier, most patients will not access it regardless of the trial data.

The other is long-term maintenance data. REDEFINE 1 ran 68 weeks. The question everyone asks about any obesity drug is: what happens at year two, year three? Does the amylin mechanism produce less plateau? Less weight regain after stopping? That data does not exist yet. It is the most interesting unanswered question about this drug class.

GLP-1 drugs broadly have a range of effects beyond weight loss — including on reward circuitry, cardiovascular risk, and metabolic markers. Whether CagriSema's amylin component adds anything to those secondary effects is an open question that the current trial program was not powered to answer.